Journal
NEOPLASIA
Volume 5, Issue 3, Pages 267-277Publisher
NEOPLASIA PRESS
DOI: 10.1016/S1476-5586(03)80058-1
Keywords
transforming growth factor-beta; prostate cancer; metastasis; probasin; transgenic mice
Categories
Funding
- NCI NIH HHS [2P30-CA-68485, P30 CA068485, R01 CA076142, U01-CA-98013, R01-CA-76142] Funding Source: Medline
Ask authors/readers for more resources
In breast and colon cancers, transforming growth factor (TGF)-beta signaling initially has an antineoplastic effect, inhibiting tumor growth, but eventually exerts a proneoplastic effect, increasing motility and cancer spread. In prostate cancer, studies using human samples have correlated the loss of the TGF-beta type II receptor (TbetaRII) with higher tumor grade. To determine the effect of an inhibited TGF-beta pathway on prostate cancer, we bred transgenic mice expressing the tumorigenic SV40 large T antigen in the prostate with transgenic mice expressing a dominant negative TbetaRII mutant (DNIIR) in the prostate. Transgene(s) and TGF-beta1 expression were identified in the prostate and decreased protein levels of plasminogen activator inhibitor type I, as a marker for TGF-beta signaling, correlated with expression of the DNIIR. Although the sizes of the neoplastic prostates were not enlarged, increased amounts of metastasis were observed in mice expressing both transgenes compared to age-matched control mice expressing only the large T antigen transgene. Our study demonstrates for the first time that a disruption of TGF-beta signaling in prostate cancer plays a causal role in promoting tumor metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available